Author

L. Flatz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1 Cell Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A.-K. Jochum· 3 shared O. H. Ali· 2 shared W. Jochum· 2 shared A. Aggarwal· 1 shared A. J. Cole· 1 shared A. L. Nguyen· 1 shared A. Muenster-Kuehnel· 1 shared A. N. Hegazy· 1 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPathology

A.-K. Jochum

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19

N. A. Lengacher, J. J. Tomlinson, A.-K. Jochum, J. Franz, O. Hasan Ali, L. Flatz, W. Jochum, J. Penninger, aSCENT-PD Investigators, C. Stadelmann-Nessler, J. M. Woulfe, M. G. Schlossmacher

This study examines neuropathological changes in the olfactory bulb and tract of COVID-19 patients, finding no significant inflammation but age-related decline in anti-CD68 reactivity and mild increases in phospho-Syn and phospho-tau signals in affected brains.

bioRxiv · Dec 18, 2023Pathology

Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4+ T cells as predictors for response to integrin α4β7-blocking therapy in patients with inflammatory bowel disease

V. Horn, C. Cancino, L. Steinheuer, B. Obermayer, K. Fritz, A. L. Nguyen, C. Plattner, D. Boesel, M. Burns, A. R. Schulz, E. Mantzivi, D. Lissner, T. Conrad, M.-F. Mashreghi, E. Sonnenberg, , A. N. Hegazy

bioRxiv · Oct 1, 2023Immunology

Tumor sialylation controls effective anti-cancer immunity in breast cancer

S. Mereiter, G. Jonsson, T. Oliveira, J. Helm, D. Hoffmann, M. Abeln, A.-K. Jochum, W. Jochum, M. J. Kellner, M. Feith, V. Tkalec, K. Wasilewska, J. Jiao, L. Emsenhuber, F. Holstein, , J. M. Penninger

This study shows that tumor sialylation suppresses anti-cancer immunity in breast cancer by altering immune cell interactions and checkpoint ligands, and that inhibiting sialylation enhances immune response and therapy effectiveness.

bioRxiv · Sep 20, 2023 · PreprintCancer Biology

Fibroblast-expressed LRRC15 suppresses SARS-CoV-2 infection and controls antiviral and antifibrotic transcriptional programs.

L. Loo, M. A. Waller, C. L. Moreno, A. J. Cole, A. O. Stella, O.-T. Pop, A.-K. Jochum, O. H. Ali, C. E. Denes, Z. Hamoudi, F. Chung, A. Aggarwal, J. K. K. Low, K. Patel, R. Siddique, , G. G. Neely

This study identifies LRRC15 as a host factor that suppresses SARS-CoV-2 infection and regulates antiviral and antifibrotic transcriptional programs in fibroblasts.

bioRxiv · Nov 9, 2021 · PreprintCell Biology

Viral infection overcomes ineffectiveness of anti-tumoral CD8+ T cell mediated cytotoxicity

F. Zhou, J. Kardash, H. Bhat, V. Duhan, S. Friedrich, J. Bezgovsek, H. Kalkavan, M. Bergerhausen, M. Schiller, Y. Machlah, T. Brandenburg, C. Hardt, M. Krolik, L. Flatz, P. Lang, K. Lang

This study shows that viral infection can restore MHC-I expression and enhance T cell function, leading to tumor regression in a mouse melanoma model.

bioRxiv · Mar 27, 2019 · PreprintImmunology